UPDATED May 21, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
HQY | US$79.31 | 3.2% | 39.5% | US$6.9b | US$100.00 | PE123.9x | E41.4% | n/a | ||
PACS | US$27.71 | 3.0% | n/a | US$4.4b | US$31.67 | PE33.9x | E31.3% | 0% | ||
AXNX | US$67.59 | 0.2% | 31.1% | US$3.4b | US$71.80 | PS8.9x | E54.1% | n/a | ||
INSP | US$152.37 | -3.9% | -49.1% | US$4.6b | US$250.73 | PS6.8x | E52.9% | n/a | ||
GMED | US$66.50 | 5.8% | 21.6% | US$8.9b | US$70.42 | PE134.8x | E40.9% | n/a | ||
STAA | US$42.51 | -2.6% | -27.9% | US$2.1b | US$52.31 | PE136.5x | E35.0% | n/a | ||
ALGN | US$264.02 | -5.1% | -6.6% | US$20.1b | US$340.69 | PE43x | E15.8% | n/a | ||
PNTG | US$23.68 | 6.6% | 83.9% | US$694.7m | US$25.50 | PE43.3x | E23.3% | n/a |